• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Primary Care Doctors Use Autonomous AI to Instantly Detect Eye Disease

Share:

November 12, 2019

– A Georgia Primary Care Clinic is now using an autonomous AI system called IDx-DR to test patients for diabetic retinopathy, a leading cause of blindness.

– IDx-DR is cleared by the FDA to make an assessment without the need for a clinician to also interpret the image or results, making it usable by healthcare providers who may not normally be involved in eye care.

– The exam typically takes 5-10 minutes. Nurses use an automated fundus camera to take pictures of the patient’s retinas – the back part of the eye.

Two primary care doctors in Georgia are closing the eye care gap for people with diabetes using artificial intelligence. Lee Herman, MD, and Michael Conlin, MD are internists at Johns Creek Primary Care, a primary care clinic in northern Atlanta. They are among the first doctors in the nation to test patients for diabetic retinopathy, a leading cause of blindness, using IDx-DR, an FDA-cleared autonomous AI system.

Impact of Diabetes on Visual Loss & Blindness

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Over 30 million Americans have diabetes and are at high risk of visual loss and blindness from diabetic retinopathy. Experts recommend annual eye exams, but a Diabetes Care study shows that as few as 15% of Medicare patients follow through on eye care referrals.

Johns Creek Primary Care participates in the Emory Healthcare Network’s Accountable Care Organization (ACO). The diabetic retinopathy exam is an important diabetes care quality measure tracked by many health systems and ACOs because early detection of diabetic retinopathy has been shown to be a cost-effective way to improve patient outcomes.

Patient Testing Results

Herman and Conlin have tested more than 150 patients using IDx-DR to date. Twenty patients who did not have a previous diagnosis of diabetic retinopathy were identified with disease by the AI system. Patients with positive results are referred on to an ophthalmologist for further monitoring and treatment to prevent vision loss.

Bill Lamm, a retired 67-year-old with diabetes from Duluth, Georgia, is a patient of Dr. Herman’s who recently received a positive result from IDx-DR.

Lamm’s ophthalmologist, Larry Heit, MD, confirmed the presence of disease but that it was not at a level that required treatment, so he switched Lamm’s follow-up eye exam from annual to every 6 months for more regular monitoring.

Lamm has high praise for the clinic’s adoption of IDx-DR. “Dr. Herman is very proactive about introducing new diagnostic procedures and technologies to enhance oversight of my general healthcare,” said Lamm. “It’s unusual for a primary care physician to have the ability to check for retinopathy. If you have patients who never go to an eye care specialist because they don’t have glasses or other vision issues, the ability to make a first-time diagnosis in primary care is important.”

Dr. Heit agrees. He is thankful that Herman and other physicians are using IDx-DR to ensure patients are tested for diabetic retinopathy.

Dr. Herman stresses that, while IDx-DR is a valuable test, patients are still encouraged to see an eye care specialist.

Source: Hit Consultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • New AI ‘Virtual Patient’ Technology to AID NHS Medical TrainingNew AI ‘Virtual Patient’ Technology to AID NHS Medical Training
  • Versius Surgical Robotic System Launched in FranceVersius Surgical Robotic System Launched in France
  • Viva Biotech’s Portfolio Company DTx Pharma Reached the Acquisition Agreement with NovartisViva Biotech’s Portfolio Company DTx Pharma Reached the Acquisition Agreement with Novartis
  • Wearables Could Transform Insurance from Reactive to ProactiveWearables Could Transform Insurance from Reactive to Proactive
  • Myeloid Therapeutics Announces $73 Million Financing to Advance mRNA-based Immunotherapy PipelineMyeloid Therapeutics Announces $73 Million Financing to Advance mRNA-based Immunotherapy Pipeline
  • Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.
  • New Transformation Capital Partner Mike Dixon Talks Insights from a Decade in Digital Health InvestingNew Transformation Capital Partner Mike Dixon Talks Insights from a Decade in Digital Health Investing
  • 12 ways AI will revolutionize healthcare in the next year12 ways AI will revolutionize healthcare in the next year

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications